{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:01:11Z","timestamp":1787166071866,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"KBP Biosciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13318-023-00837-5","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T12:01:30Z","timestamp":1687694490000},"page":"397-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics and Drug\u2013Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo"],"prefix":"10.1007","volume":"48","author":[{"given":"Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4389-4901","authenticated-orcid":false,"given":"Jay","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,25]]},"reference":[{"issue":"1","key":"837_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"A Levin","year":"2013","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang H, White CT, Winearls CG. Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1\u2013150. https:\/\/doi.org\/10.1038\/kisup.2012.73.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"837_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5527\/wjn.v10.i4.59","volume":"10","author":"P Hansrivijit","year":"2021","unstructured":"Hansrivijit P, Chen Y-J, Lnu K, Trongtorsak A, Puthenpura MM, Thongprayoon C, Bathini T, Mao MA, Cheungpasitporn W. Prediction of mortality among patients with chronic kidney disease: A systematic review. World J Nephrol. 2021;10(4):59\u201375. https:\/\/doi.org\/10.5527\/wjn.v10.i4.59.","journal-title":"World J Nephrol."},{"key":"837_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151\u2013210. https:\/\/doi.org\/10.1016\/s0140-6736(17)32152-9.","DOI":"10.1016\/s0140-6736(17)32152-9"},{"issue":"2","key":"837_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2016","unstructured":"Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73\u201381. https:\/\/doi.org\/10.1038\/nrneph.2015.173.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"837_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1681\/ASN.V1281713","volume":"12","author":"AR Nissenson","year":"2001","unstructured":"Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713\u201320. https:\/\/doi.org\/10.1681\/ASN.V1281713.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"837_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ndt\/gfu015","volume":"30","author":"M Burnier","year":"2015","unstructured":"Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant. 2015;30(1):39\u201344. https:\/\/doi.org\/10.1093\/ndt\/gfu015.","journal-title":"Nephrol Dial Transplant"},{"key":"837_CR7","volume-title":"Slowing diabetic kidney disease progression: Where do we stand today? Chronic Kidney Disease and Type 2 Diabetes","author":"SC Naaman","year":"2021","unstructured":"Naaman SC, Bakris GL. Slowing diabetic kidney disease progression: Where do we stand today? Chronic Kidney Disease and Type 2 Diabetes. Arlington, VA: American Diabetes Association; 2021."},{"issue":"2","key":"837_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/2249-4863.154630","volume":"4","author":"JP Yaxley","year":"2015","unstructured":"Yaxley JP, Thambar SV. Resistant hypertension: An approach to management in primary care. J Family Med Prim Care. 2015;4(2):193\u20139. https:\/\/doi.org\/10.4103\/2249-4863.154630.","journal-title":"J Family Med Prim Care."},{"issue":"2","key":"837_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: A meta-analysis of data from 32. million patients. Heart. 2019;105(2):98\u2013105. https:\/\/doi.org\/10.1136\/heartjnl-2018-313599.","journal-title":"Heart."},{"key":"837_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.0000000000000084","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 2018. https:\/\/doi.org\/10.1161\/hyp.0000000000000084.","journal-title":"Hypertension."},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"I Lazich","year":"2014","unstructured":"Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333\u20139. https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.008.","journal-title":"Semin Nephrol"},{"issue":"3","key":"837_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","volume":"52","author":"M Epstein","year":"2021","unstructured":"Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: From Hans Selye to the present. Am J Nephrol. 2021;52(3):209\u201316. https:\/\/doi.org\/10.1159\/000515622.","journal-title":"Am J Nephrol"},{"issue":"1","key":"837_CR13","doi-asserted-by":"publisher","first-page":"T23","DOI":"10.1530\/joe-17-0060","volume":"234","author":"PJ Fuller","year":"2017","unstructured":"Fuller PJ, Yang J, Young MJ. Coregulators as mediators of mineralocorticoid receptor signalling diversity. J Endocrinol. 2017;234(1):T23\u201334. https:\/\/doi.org\/10.1530\/joe-17-0060.","journal-title":"J Endocrinol"},{"issue":"3","key":"837_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/hypertensionaha.120.16397","volume":"77","author":"A Sakima","year":"2021","unstructured":"Sakima A, Arima H, Matayoshi T, Ishida A, Ohya Y. Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function. Hypertension. 2021;77(3):929\u201337. https:\/\/doi.org\/10.1161\/hypertensionaha.120.16397.","journal-title":"Hypertension"},{"issue":"1","key":"837_CR15","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/joe-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340. https:\/\/doi.org\/10.1530\/joe-16-0600.","journal-title":"J Endocrinol"},{"issue":"3","key":"837_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/cjn.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542\u201351. https:\/\/doi.org\/10.2215\/cjn.04750908.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"837_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AHM, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, Van Den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127. https:\/\/doi.org\/10.1186\/s12882-016-0337-0.","journal-title":"BMC Nephrol"},{"issue":"10","key":"837_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","volume":"30","author":"B Pitt","year":"2021","unstructured":"Pitt B, Jaisser F, Bakris G. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021;30(10):1017\u201323. https:\/\/doi.org\/10.1080\/13543784.2021.1985462.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"837_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/hypertensionaha.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension. 2021;78(1):74\u201381. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17073.","journal-title":"Hypertension"},{"key":"837_CR20","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). In vitro drug interaction studies--cytochrome P450 enzyme- and transporter-mediated drug interactions. Silver Spring, MD; 2020."},{"key":"837_CR21","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clinical drug interaction studies--cytochrome P450 enzyme- and transporter-mediated drug interactions. Silver Spring, MD; 2020."},{"key":"837_CR22","unstructured":"Tx ZB, Ni, S. Pharmacokinetics and safety of KBP-5074 in Phase 1 single and multiple ascending dose studies. American Society of Nephrology Kidney Week Meeting; Chicago, IL2016."},{"key":"837_CR23","doi-asserted-by":"publisher","unstructured":"Chen Y, Cabalu TD, Callegari E, Einolf H, Liu L, Parrott N, Peters SA, Schuck E, Sharma P, Tracey H, Upreti VV, Zheng M, Zhu AZX, Hall SD. Recommendations for the design of clinical drug\u2013drug interaction studies With itraconazole using a mechanistic physiologically\u2010based pharmacokinetic model. CPT: Pharmacomet Syst Pharmacol. 2019;8(9):685-95. https:\/\/doi.org\/10.1002\/psp4.12449.","DOI":"10.1002\/psp4.12449"},{"issue":"2","key":"837_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jcph.562","volume":"56","author":"L Liu","year":"2015","unstructured":"Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O\u2019Mara E, Rogge M, Stoch A, Robertson SM. Best practices for the use of itraconazole as a replacement for ketoconazole in drug\u2013drug interaction studies. J Clin Pharmacol. 2015;56(2):143\u201351.","journal-title":"J Clin Pharmacol"},{"key":"837_CR25","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0341-y","author":"AJ Kapetas","year":"2019","unstructured":"Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A. Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction. AAPS J. 2019. https:\/\/doi.org\/10.1208\/s12248-019-0341-y.","journal-title":"AAPS J."},{"key":"837_CR26","doi-asserted-by":"crossref","unstructured":"Connaire J, Bush M, Ruckle J, Yang F, Liu J, Tan X, Wang P, Zhou T, Zhang M, Benn V. Safety and pharmacokinetics of a novel non-steroidal mineralocorticoid receptor antagonist, KBP-5074, in hemodialysis and non-hemodialysis patients with severe chronic kidney disease. 2020;371:1513.","DOI":"10.1101\/2020.05.12.20053314"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00837-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00837-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00837-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T22:14:22Z","timestamp":1688595262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00837-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,25]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00837-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,25]]},"assertion":[{"value":"30 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors would like to acknowledge the editorial assistance of Terri Levine, PhD, and Ishita Chatterjee, PhD, of ProPharma Group in the development of this manuscript that was funded by KBP Biosciences USA, Inc., Princeton, NJ in accordance with Good Publication Practice (GPP22) guidelines. The authors thank the volunteers who participated in the clinical studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}},{"value":"Participated in research design: Ping Wang, Jay Zhang, Fred Yang. Administrative support for study: Xiaojuan Tan, Jinrong Liu. Performed data analysis: Ping Wang, Jay Zhang. Wrote or contributed to the writing of the manuscript: Ping Wang, Jay Zhang. Medical oversight: James McCabe.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"The nonclinical and clinical DDI studies were supported by KBP Biosciences Co., Ltd., Jinan, China.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors were employees of KBP Biosciences USA, Inc., Princeton, NJ (F. Yang, J. McCabe, J. Zhang) or KBP Biosciences Co., Ltd., Jinan, China. (P. Wang, J. Liu, X. Tan). There were no other competing interests to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The clinical DDI study was conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable laws and regulations. The study was approved by WCG IRB (Study#: 8450126; Approval Date October 13, 2020).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Custom software or code used during the study are available from the corresponding author on reasonable request.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}